This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Patel SH , Uzzo RG , Larcher A , Peyronnet B , Lane BR , Pruthi D , Reddy M , Capitanio U , Joshi S , Noyes S , Eldefrawy A , Ghali F , Meagher MF , Hamilton ZA , Yim K , Nasseri R , Bradshaw AW , Dey S , Kirmiz S , Wan F , Liss MA , Bensalah K , Montorsi F , Derweesh IH
Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Clin Genitourin Cancer. 2020 Dec;18(6) :e723-e729
PMID: 32600941 URL: https://www.ncbi.nlm.nih.gov/pubmed/32600941
AbstractBACKGROUND: The efficacy of partial nephrectomy (PN) in setting of pT3a pathologic-upstaged renal cell carcinoma (RCC) is controversial. We compared oncologic and functional outcomes of radical nephrectomy (RN) and PN in patients with upstaged pT3a RCC. PATIENTS AND METHODS: This was a multicenter retrospective analysis of patients with cT1-2N0M0 RCC upstaged to pT3a postoperatively. The primary outcome was recurrence-free survival, with secondary outcomes of overall survival and de novo estimated glomular filtration rate (eGFR) < 60. Multivariable analysis was performed to identify predictive factors for oncologic outcomes. Kaplan-Meier analyses (KMA) were obtained to elucidate survival outcomes. RESULTS: A total of 929 patients had pT3a upstaging (686 [72.6%] RN; 243 [25.7%] PN; mean follow-up, 48 months). Tumor size was similar (RN 7.7 cm vs. PN 7.3 cm; P = .083). PN had decreased DeltaeGFR (6.1 vs. RN 19.4 mL/min/1.73m(2); P < .001) and de novo eGFR < 60 (9.5% vs. 21%; P = .008). Multivariable analysis for recurrence showed increasing RENAL score (hazard ratio [HR], 3.8; P < .001), clinical T stage (HR, 1.8; P < .001), positive margin (HR, 1.57; P = .009), and high grade (HR, 1.21; P = .01) to be independent predictors, whereas surgery was not (P = .076). KMA revealed 5-year recurrence-free survival for cT1-upstaged PN, cT1-upstaged RN, cT2-upstaged PN, and cT2-upstaged RN of 79%, 74%, 70%, and 51%, respectively (P < .001). KMA revealed 5-year overall survival for cT1-upstaged PN, cT1-upstaged RN, cT2-upstaged PN, and cT2-upstaged RN of 64%, 65.2%, 56.4%, and 55.2%, respectively (P = .059). CONCLUSIONS: In pathologically upstaged pT3a RCC, PN did not adversely affect risk of recurrence and provided functional benefit. Surgical decision-making in patients at risk for T3a upstaging should be individualized and driven by tumor as well as functional risks.
Notes1938-0682 Patel, Sunil H Uzzo, Robert G Larcher, Alessandro Peyronnet, Benoit Lane, Brian R Pruthi, Deepak Reddy, Madhumitha Capitanio, Umberto Joshi, Shreyas Noyes, Sabrina Eldefrawy, Ahmed Ghali, Fady Meagher, Margaret F Hamilton, Zachary A Yim, Kendrick Nasseri, Ryan Bradshaw, Aaron W Dey, Sumi Kirmiz, Samer Wan, Fang Liss, Michael A Bensalah, Karim Montorsi, Francesco Derweesh, Ithaar H Journal Article United States Clin Genitourin Cancer. 2020 Dec;18(6):e723-e729. doi: 10.1016/j.clgc.2020.05.002. Epub 2020 May 11.